Lagali Neil, Griffith May, Fagerholm Per, Merrett Kimberley, Huynh Melissa, Munger Rejean
University of Ottawa Eye Institute, Ottawa, Ontario, Canada.
Invest Ophthalmol Vis Sci. 2008 Sep;49(9):3895-902. doi: 10.1167/iovs.07-1354. Epub 2008 Apr 11.
To compare reinnervation in recombinant human collagen-based corneal substitutes with allografts during a 1-year postimplantation follow-up period in pigs. A retrospective comparison to innervation in porcine collagen-based biosynthetic grafts was also performed.
Pigs received a corneal allograft or a substitute made of either recombinant human type-I or -III collagen. In vivo confocal microscopic examination of the central cornea of surgical and untouched control eyes before surgery and at 2, 6, and 12 months after surgery was performed to quantify the number, density, and diameter of nerves at various corneal depths.
By 12 months after surgery, the number and density of regenerated nerves in the anterior and deep anterior corneal stroma recovered to preoperative and control levels in both types of substitute grafts and in the allografts. In the subepithelial and subbasal regions, however, significantly fewer nerves were detected relative to those in control subjects at 12 months, regardless of graft type (P < 0.05), similar to the behavior of porcine collagen-based biosynthetic grafts. An absence of thick stromal nerve trunks (diameter, >10 mum) in all grafts, irrespective of material type, indicated that nerve regeneration in grafts was accompanied by persistent morphologic changes.
Nerve regeneration in recombinant human collagen-based biosynthetic corneal grafts proceeded similarly to that in allograft tissue, demonstrating the suitability of recombinant human collagen constructs as nerve-friendly corneal substitutes. Furthermore, only minor differences were noted between type-I and -III collagen grafts, indicating an insensitivity of nerve regeneration to initial collagen type.
在猪的1年植入后随访期内,比较重组人胶原蛋白基角膜替代物与同种异体移植物中的神经再支配情况。还对猪胶原蛋白基生物合成移植物中的神经支配进行了回顾性比较。
猪接受角膜同种异体移植物或由重组人I型或III型胶原蛋白制成的替代物。在手术前以及手术后2、6和12个月,对手术眼和未受影响的对照眼的中央角膜进行体内共聚焦显微镜检查,以量化不同角膜深度处神经的数量、密度和直径。
术后12个月时,两种替代移植物和同种异体移植物中,前角膜基质和深前角膜基质中再生神经的数量和密度均恢复到术前和对照水平。然而,在12个月时,无论移植物类型如何,相对于对照受试者,在角膜上皮下和基底膜下区域检测到的神经明显较少(P < 0.05),这与猪胶原蛋白基生物合成移植物的情况相似。所有移植物中均不存在粗大的基质神经干(直径>10μm),无论材料类型如何,这表明移植物中的神经再生伴随着持续的形态学变化。
重组人胶原蛋白基生物合成角膜移植物中的神经再生过程与同种异体移植物相似,表明重组人胶原蛋白构建体作为神经友好型角膜替代物的适用性。此外,I型和III型胶原蛋白移植物之间仅观察到微小差异,表明神经再生对初始胶原蛋白类型不敏感。